Company Filing History:
Years Active: 2016
Title: Yu-Lin Leu: Innovator in Anti-Cancer Prodrugs
Introduction
Yu-Lin Leu is a prominent inventor based in Tainan, Taiwan. She has made significant contributions to the field of cancer treatment through her innovative research and development of anti-cancer prodrugs. Her work focuses on enhancing the efficacy and safety of cancer therapies.
Latest Patents
Yu-Lin Leu holds a patent for BQC-G, a tumor-selective anti-cancer prodrug. This invention relates to the synthesis of a second-generation camptothecin glucuronide prodrug, which is derived from a potent anticancer camptothecin derivative known as 5,6-dihydro-4H-benzo[de]quinoline-camptothecin (BQC). BQC-G is over 4000 times more water-soluble than BQC and demonstrates good stability in human plasma. It serves as an excellent substrate for enzymatic hydrolysis by bacterial and human β-glucuronidases. Notably, BQC-G is approximately 30 times less toxic than BQC, but it exhibits similar toxicity to BQC after the hydrolysis of the glucuronide moiety by β-glucuronidase. In the presence of human serum albumin, BQC-G shows lower cytotoxicity (IC=1080 nM) but can be activated by β-glucuronidase to display potent activity (IC=13.3 nM).
Career Highlights
Yu-Lin Leu is affiliated with Academia Sinica, where she conducts her research. Her work has garnered attention for its potential to improve cancer treatment outcomes. She has successfully developed a prodrug that addresses the limitations of existing therapies, showcasing her innovative approach to drug design.
Collaborations
Yu-Lin Leu has collaborated with notable researchers, including Zeljko M Prijovic and Steve R Roffler. These collaborations have contributed to the advancement of her research and the development of her patented inventions.
Conclusion
Yu-Lin Leu is a trailblazer in the field of anti-cancer drug development. Her invention of BQC-G represents a significant advancement in cancer therapy, highlighting her dedication to improving patient outcomes. Her contributions to the scientific community continue to inspire future innovations in cancer treatment.